ºÚÁÏÍø

Pancreatic cancer; Clinical roles; Pancreas

Introduction

The clinical stage, lymph node and/or visceral involvement, tumour size and differentiation, involvement of the resection margins, and serum CA19-9 level are a few major variables that have varying relationships with the prognosis of pancreatic cancer. The prognosis for pancreatic cancer is quite bad for the vast majority of patients, yet the varying presence of these characteristics might modulate survival within a constrained time period. Clinical symptoms that exist prior to diagnosis and/or throughout treatment have recently received attention as additive prognostic markers. As a result, we made the decision to include some of the most prevalent early symptoms in our analysis of the variables influencing the prognosis of our cohort of patients with pancreatic cancer. We sought to confirm the prognostic significance of each symptom, paying close attention to diagnostic delays as well as connections to other established clinical and pathological markers [1, 2, and 3].

Patients

The measures investigated were overall and relative survival. Several regressions applied to the proportional-hazards model were used to perform the multivariate analysis. Results: The time to diagnosis and surgery were the two factors that were statistically significant among all the clinical, pathological, and therapeutically parameters investigated. Weight loss had the longest mean time to diagnosis among symptoms, while pain was the shortest, with commensurate disparities in survival. In terms of relative survival, these variations in observed survival were mostly verified. Conclusions: The poor prognosis of pancreatic cancer appears to be partially determined by the length of time it takes to make a diagnosis, which is then influenced by the nature of the presenting symptoms [4, 5].

We treated 170 individuals with newly discovered pancreatic cancer between 2001 and 2010 (ten years). Everyone provided their written approval for data analysis in accordance with the Institute’s ethical committee criteria. Re-evaluation of the histological or cytological specimens led to the exclusion of patients with neuroendocrine, ampullary, or duodenal cancers from this collection [6, 7].

It presents the patients’ primary clinical characteristics, while Table 2 lists their comorbidities. Three-quarters of all patients in our study have advanced clinical stages, which is consistent with the overall characteristics of many other series in the literature (III or IV). In a population with a mean age at diagnosis, the prevalence and variety of comorbidities are within reasonable bounds [8, 9].

Conclusion

The biological characteristics and aggressiveness of the tumour, as well as the efficacy of treatments—which, although still having a limited impact on the disease’s natural course—determine the prognosis for individuals with pancreatic carcinoma. In fact, the impact of chemotherapy that emerged from our research appeared to be significant, but short-lived and restricted to the first eight months. Chemotherapy’s independent contribution to pancreatic cancer patients’ survival [10].

Acknowledgment

None.

Conflict of Interest

The writers affirm that they have no business or personal ties to any individuals or organisations that would improperly influence this work.

1. Kim H, Ding Z, Lee M H, Lim K, Yoon G, et al.( 2016) . Adv Energy Mater 6: 1600943-1600945.

,

2. Petri R, Giebel T, Zhang B, Schünemann J H, Herrmann C (2015) . Int J Precis Eng Manuf Green Technol 2: 263-268.

,

3. Rempel J, Barnett B, Hyung Y PHEV (2013) . In Proceedings of the TIAX LLC, Lexington, KY, USA 14.

,

4. Ellingsen L A W, Majeau-Bettez G, Singh B, Srivastava A K, Valoen L O, et al. (2014) . J Ind Ecol 18: 113-124.

, ,

5. Warner J T (2015) The Handbook of Lithium-Ion Battery Pack Design: Chemistry, Components, Types and Terminology, Elsevier: Amsterdam, The Netherlands, ISBN 978-0-12-801456-1.
6. Pistoia G (Ed) (2014) .
7. Ponrouch A, Marchante E, Courty M, Tarascon J M, Palacín M R (2012) . Energy Environ Sci 5: 8572-8575.

, ,

8. Ponrouch A, Monti D, Boschin A, Steen B, Johansson P, et al. (2014) . J Mater Chem 3: 22-42.
9. Alibaba Group18650, 26650, 32650 Cylinder Cell Case with PTC for Lithium Battery. Alibaba.com, 6 March 2018.
10. Nitta N, Wu F, Lee J T, Yushin G (2015) . Mater Today18: 252-264.

,